Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease.
To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET/CT).
Patients with psoriasis and healthy controls underwent baseline 18F-FDG PET/CT imaging. Patients with moderate-to-severe psoriasis were treated with ustekinumab and underwent 18F-FDG PET/CT again after a Psoriasis Area and Severity Index of 75 was achieved.
After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P < .05).
Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population.
Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.Le texte complet de cet article est disponible en PDF.
Key words : cardiovascular disease, metabolic syndrome, PET/CT, positron emission tomography–computed tomography, psoriasis, ustekinumab
Abbreviations used : BMI, BSA, CVD, PASI, PASI75, 18F-FDG PET/CT
| Byung-Soo Kim and Won-Ku Lee contributed equally to this work.
| Funding sources: None.
| Conflicts of interest: None disclosed.